Description

DTP3 TFA is a potent and selective GADD45β/MKK7 (growth arrest and DNA-damage-inducible β/mitogen-activated protein kinase kinase 7) inhibitor. DTP3 TFA targets an essential, cancer-selective cell-survival module downstream of the NF-κB pathway[1].–80°C, 2 years; -20°C, 1 year (Powder, sealed storage, away from moisture and light)–Cancer-Kinase/protease–C28H36F3N7O7—-[1]Tornatore L, et al. Preclinical toxicology and safety pharmacology of the first-in-class GADD45β/MKK7inhibitor and clinical candidate, DTP3. Toxicol Rep. 2019 Apr 19;6:369-379.|[2]Tornatore L, et al. Cancer-selective targeting of the NF-κB survival pathway with GADD45β/MKK7 inhibitors. Cancer Cell. 2014 Oct 13;26(4):495-508.–2759216-46-9–639.62–98.00–O=C(N[C@H](CC1=CC=CC=C1)C(N)=O)[C@H](NC([C@H](NC(C)=O)CC2=CC=C(O)C=C2)=O)CCCNC(N)=N.OC(C(F)(F)F)=O–Cancer–DMSO : 50 mg/mL (ultrasonic)|H2O : 100 mg/mL (ultrasonic)–DNA/RNA Synthesis;JNK—-Cell Cycle/DNA Damage;MAPK/ERK Pathway–Peptides